Two New Lynx Spider Species of Hamadruas and Oxyopes and the First Record of Hamadruas Thorell, 1887 (Araneae: Oxyopidae) from Wai, Maharashtra, India

Posted by
  Two New Lynx Spider Species of Hamadruas and Oxyopes and the First Record of Hamadruas Thorell, 1887 (Araneae: Oxyopidae) from Wai, Maharashtra, India Abstract The present study reports two oxyopid spider species from Wai, Satara District, Maharashtra, India, based on morphological examination of specimens collected from the Kisan Veer Mahavidyalaya campus. The specimens were collected using hand-collection and sweep-net methods, preserved in 70% ethanol, and examined under a stereotrinocular microscope. Diagnostic structures, including the female epigyne and male palp, were studied after dissection, and distribution maps were prepared using QGIS. Hamadruas kvmensis sp. nov. is characterised by distinct dark elongated spermathecal lobes, a rounded central region forming the median fertilisation duct, curved copulatory ducts, and a male palp with an elongated curved cymbium, large bulb, prominent tegulum, slender embolus, conductor, tibial apophysis and sensory setae. Oxyopes wai...

Spider Venom-Derived Peptide Exhibits Dual Anti-Inflammatory and Antioxidative Activities in LPS-Stimulated BEAS-2B Cells

Posted by

 


Spider Venom-Derived Peptide Exhibits Dual Anti-Inflammatory and Antioxidative Activities in LPS-Stimulated BEAS-2B Cells

Abstract

Most respiratory diseases are driven by excessive airway inflammation and oxidative stress, yet current therapies often lack durable efficacy or are unsafe. Host-defense peptides, commonly enriched in animal venoms, offer diverse, target-selective scaffolds for new therapeutics. In this study, we aimed to discover a novel bioactive peptide with therapeutic potential on respiratory tract damage by utilizing Nephila clavata venom gland transcriptome. Using in silico analysis and machine learning-based functional prediction, we designed a peptide, NC-CV, expected to have dual anti-inflammatory and antioxidant activities with low cytotoxicity. In experimental validation, NC-CV improved human bronchial epithelial BEAS-2B cell viability under lipopolysaccharide (LPS) exposure while reducing LPS-induced pro-inflammatory cytokine expression and intracellular reactive oxygen species (ROS) generation. Mechanistic studies and molecular docking simulations indicated that NC-CV prevents toll-like receptor 4 signaling activation, suppressing nuclear factor κB and mitogen-activated protein kinase pathways. Moreover, the antioxidant activity of NC-CV was primarily based on direct intracellular ROS scavenging rather than the induction of endogenous antioxidant enzymes. Collectively, these findings demonstrated that the venom-derived peptide NC-CV disrupts the self-reinforcing cycle involving inflammatory signaling and oxidative stress in airway epithelium, highlighting its promise as a therapeutic candidate for respiratory disease.